These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22989076)

  • 1. Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
    Onishi M; Ichikawa T; Kurozumi K; Fujii K; Yoshida K; Inoue S; Michiue H; Chiocca EA; Kaur B; Date I
    Neuropathology; 2013 Apr; 33(2):162-74. PubMed ID: 22989076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas.
    Inoue S; Ichikawa T; Kurozumi K; Maruo T; Onishi M; Yoshida K; Fujii K; Kambara H; Chiocca EA; Date I
    World Neurosurg; 2012 Dec; 78(6):670-82. PubMed ID: 22120277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
    Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
    Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics-based analysis of invasion-related proteins in malignant gliomas.
    Maruo T; Ichikawa T; Kanzaki H; Inoue S; Kurozumi K; Onishi M; Yoshida K; Kambara H; Ouchida M; Shimizu K; Tamaru S; Chiocca EA; Date I
    Neuropathology; 2013 Jun; 33(3):264-75. PubMed ID: 23116197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annexin A2 regulates angiogenesis and invasion phenotypes of malignant glioma.
    Onishi M; Ichikawa T; Kurozumi K; Inoue S; Maruo T; Otani Y; Fujii K; Ishida J; Shimazu Y; Yoshida K; Michiue H; Antonio Chiocca E; Date I
    Brain Tumor Pathol; 2015 Jul; 32(3):184-94. PubMed ID: 25697644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cilengitide treatment for malignant glioma: current status and future direction.
    Kurozumi K; Ichikawa T; Onishi M; Fujii K; Date I
    Neurol Med Chir (Tokyo); 2012; 52(8):539-47. PubMed ID: 22976135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.
    Otani Y; Ichikawa T; Kurozumi K; Inoue S; Ishida J; Oka T; Shimizu T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Michiue H; Date I
    Oncogene; 2018 Feb; 37(6):777-786. PubMed ID: 29059154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilengitide induces autophagy-mediated cell death in glioma cells.
    Lomonaco SL; Finniss S; Xiang C; Lee HK; Jiang W; Lemke N; Rempel SA; Mikkelsen T; Brodie C
    Neuro Oncol; 2011 Aug; 13(8):857-65. PubMed ID: 21788343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilengitide inhibits metastatic bone colonization in a nude rat model.
    Bretschi M; Merz M; Komljenovic D; Berger MR; Semmler W; Bäuerle T
    Oncol Rep; 2011 Oct; 26(4):843-51. PubMed ID: 21725616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
    Maurer GD; Tritschler I; Adams B; Tabatabai G; Wick W; Stupp R; Weller M
    Neuro Oncol; 2009 Dec; 11(6):747-56. PubMed ID: 19221171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy of cilengitide with belotecan against experimental glioblastoma.
    Kim YH; Lee JK; Kim B; DeWitt JP; Lee JE; Han JH; Kim SK; Oh CW; Kim CY
    Int J Cancer; 2013 Aug; 133(3):749-56. PubMed ID: 23354807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
    Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
    Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
    Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
    Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
    Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
    Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a canine glioma cell line as related to established experimental brain tumor models.
    Rainov NG; Koch S; Sena-Esteves M; Berens ME
    J Neuropathol Exp Neurol; 2000 Jul; 59(7):607-13. PubMed ID: 10901232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
    Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
    Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study.
    Bäuerle T; Komljenovic D; Merz M; Berger MR; Goodman SL; Semmler W
    Int J Cancer; 2011 May; 128(10):2453-62. PubMed ID: 20648558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
    Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
    Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.
    MacDonald TJ; Vezina G; Stewart CF; Turner D; Pierson CR; Chen L; Pollack IF; Gajjar A; Kieran MW
    Neuro Oncol; 2013 Oct; 15(10):1438-44. PubMed ID: 24014381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.
    Nagaraja TN; Aryal MP; Brown SL; Bagher-Ebadian H; Mikkelsen T; Yang JJ; Panda S; Keenan KA; Cabral G; Ewing JR
    PLoS One; 2013; 8(12):e84493. PubMed ID: 24376814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.